intervention

4-Methylcinnamic acid is a cinnamic acid analog that can be used as an intervention catalyst to overcome antifungal tolerance. 4-Methylcinnamic acid can improve the potency of cell wall-disrupting agents.

Fosphenytoin is a phosphate prodrug that can be used as an alternative to intravenous phenytoin for the acute intervention of seizures.Fosphenytoin is hydrolyzed to anticonvulsant phenytoin when administered parenterally.Fosphenytoin can be used in a variety of delivery modes such as intravenous and intraperitoneal.Fosphenytoin can be used in a variety of delivery modes such as intravenous and intraperitoneal.

Bendazac L-lysine (Bendazaco lisina) is an agent introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

Cinnamic acid (β-Phenylacrylic acid) has potential use in cancer intervention,The concentration causing a 50% reduction of cell proliferation (IC50) ranged from 1 to 4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

Efpeglenatide is a long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor. Efpeglenatide improves insulin sensitivity, lowers blood glucose levels, and delays weight gain in diabetic and obese mouse models. Efpeglenatide has been applied in Type 2 diabetes research, providing an efficient experimental tool and preclinical evaluation value for developing metabolic disease intervention strategies, investigating weight loss mechanisms, and exploring insulin signaling regulation pathways.

Iso-SLR 080811 is an isomer of SLR 080811, suitable for relevant research in the life sciences. SLR080811 is a selective SphK2 inhibitor (Ki=1.3 μM) that elevates blood S1P levels in wild-type mice, reduces S1P levels in sphk1 knockout mice, and leaves S1P levels unchanged in SphK2 knockout mice.

KBP-7018 is a potent and highly selective tyrosine kinase inhibitor that simultaneously targets three key fibrotic-associated kinases, including c-KIT, RET, and PDGFR, with IC50 values of 10 nM, 7.6 nM, and 25 nM respectively, and is therefore widely applicable for mechanistic research into fibrotic signaling pathways, kinase-driven disease progression, and pharmacological intervention strategies aimed at modulating aberrant tyrosine kinase activity.

CL-82198, a selective MMP-13 inhibitor, serves as a pharmacological intervention to halt the progression of osteoarthritis (OA). Its mechanism of action involves binding to the S1' pocket of MMP-13, ensuring its selectivity and preventing inhibition of other MMPs.

Dichlorophenyl-ABA is a transthyretin (TTR) amyloid fibril formation inhibitor that effectively suppresses pathological protein aggregation, inhibiting more than 80% of aggregate formation in TTR L55P-expressing cells, Dichlorophenyl-ABA is widely employed in amyloidosis research to study TTR stabilization, aggregation mechanisms, and therapeutic intervention strategies.

MMV030084 is a potent PfPKG inhibitor that displays nanomolar-level activity against liver-stage Plasmodium parasites in HepG2 cells and synchronized schizont stages of both drug-sensitive and multidrug-resistant strains, selectively inhibits male gamete exflagellation, and mechanistically targets cGMP-dependent protein kinase with sub-nanomolar potency in recombinant assays, establishing MMV030084 as a valuable antimalarial lead for multistage lifecycle intervention.

Cardionogen-2 is a biphasic cardiac regulatory agent that can either promote or inhibit heart formation depending on the intervention stage. It inhibits Wnt/β-catenin-dependent transcription in mouse embryonic stem cells and zebrafish embryos.

P2X4-IN-1 is an orally bioavailable P2X4 receptor antagonist. P2X4-IN-1 has potential application value in disease intervention research.

Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI)

PKUMDL-WQ-2201 is a PHGDH non-NAD⁺-competing allosteric inhibitor with micromolar potency against wild-type and mutant PHGDH enzymes, effectively suppressing de novo serine biosynthesis in cancer cells and reducing tumor growth, PKUMDL-WQ-2201 provide a metabolic intervention strategy for studying serine-dependent tumor metabolism.

Givosiran (ALN-AS1) is a small interfering RNA compound that selectively targets hepatic aminolevulinate synthase 1 (ALAS1) mRNA, leading to efficient downregulation of ALAS1 expression and consequent inhibition of neurotoxic δ-aminolevulinic acid and porphobilinogen accumulation. Givosiran provides a mechanism-driven research tool with significant relevance for studying metabolic dysregulation and therapeutic intervention strategies in acute intermittent porphyria.

Yangonin (Y100550) is a novel CB receptor ligand, it exhibits affinity for the human recombinant CB receptor. Yangonin (Y100550) could be a valuable candidate for the intervention of NF-κB-dependent pathological conditions such as inflammation.

SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is critical for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.

SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, with IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme (3CLpro), making it an attractive candidate for intervention strategies and holds significant promise in the development of specific antivirals against SARS-CoV-2.

FTI-277 hydrochloride is a farnesyl transferase inhibitor and highly potent Ras CAAX peptidomimetic that antagonizes both H-Ras and K-Ras oncogenic signaling pathways, FTI-277 hydrochloride additionally inhibits hepatitis delta virus infection, making it a valuable compound for studying Ras-driven oncogenesis, protein prenylation, and antiviral intervention strategies.

Spirapril hydrochloride (SCH 33844 hydrochloride) is a potent angiotensin converting enzyme inhibitor with antihypertensive activity that competitively blocks the conversion of angiotensin I to angiotensin II, functions as an orally active proagent of spiraprilat, and is extensively utilized in cardiovascular research focused on hypertension and congestive heart failure pathophysiology and therapeutic intervention.

SGK1-IN-3 (compound 3a) is a potent serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibitor with an IC50 value of less than 1 μM, SGK1-IN-3 is applied in musculoskeletal research to explore SGK1-mediated signaling pathways and its potential role in osteoarthritis pathogenesis and therapeutic intervention.

H-β-HoPhe-OH.HCl is a phenylalanine derivative. H-β-HoPhe-OH.HCl, like other amino acids and amino acid derivatives, is commercially utilized as an ergogenic supplement that influences anabolic hormone secretion, provides energy during exercise, enhances mental performance under stress-related tasks, and prevents exercise-induced muscle damage, demonstrating its value as a dietary intervention for performance optimization and physiological enhancement.

Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor PF-06651600 led to its evaluation in several human clinical studies. JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies.

1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or act